MicroPort® Won 2018 Shanghai Municipality Gold Quality Prize

[2019-02-25]

Shanghai, China – The Shanghai Municipal People's Government published the Decision to Commend the Organizational and Individual Winners of the 2018 Shanghai Municipality Government Quality Awards recently. Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was awarded the 2018 Shanghai Municipality Gold Quality Prize, which is included in the government quality awards, becoming the only winner of the honor from the medical device sector since the establishment of the prize.
 
The Shanghai Municipality Government Quality Awards aims to guide the various industries in Shanghai to improve quality management, pursue excellent results, and fully put to good use the two-wheel drive of quality and innovation in the economic and social development, so as to further elevate Shanghai's general quality level and urban core competitiveness. The Shanghai Municipality Gold Quality Prize was launched in 2001 and is mainly awarded to the organizations that demonstrate outstanding quality management level, strong capability to innovate independently, industry leading position in terms of economic and social performance in Shanghai, and a benchmark role in their respective industries citywide. On the other hand, the organizations have achieved extraordinary innovative results with regard to the innovation in quality management model, quality management method and brand building, as well as the research in quality-related technologies.
 
The Shanghai Municipality Government Quality Awards adopt the National Standard GB/T 19580 Criteria for Performance Excellence as the standard to evaluate the organizational management maturity. Among the world's national quality awards, the most famous and influential ones are Deming Prize of Japan, Malcolm Baldrige National Quality Award of the US and EFQM Excellence Award of Europe. In order to guide the organizations to continuously pursue excellence, lift the organizations' overall business quality and increase the corporate competitiveness, the Quality Management Department of the former General Administration of Quality Supervision, Inspection and Quarantine of China initiated, and China National Institution of Standardization drafted and published the National Standard GB/T 19580 Criteria for Performance Excellence. The standard has evolved from the evaluation criteria of Malcolm Baldrige National Quality Award with the basically same framework and structures. It provides the benchmark for the Chinese corporations to pursue excellence and conduct self-evaluation.
 
Since its founding in 1998, MicroPort® has placed Quality on the top of all the eight company core values and actively pressed ahead with the building of a corporate culture based on quality, so as to make a common value concept take shape among the employees. The MicroPort® employees deeply understand that our products are directly related to each patient's life and their family's happiness. Even the minute miscalculation from us can cause irrevocable consequence to our patients. Because of this belief, we ask each of our members to be enthusiastic about our work, putting every effort into ensuring the perfect quality of our products. MicroPort® puts product quality management at the first place and fuses different countries' regulations on medical devices with ISO9001 and ISO13485 as the basic framework to form the company's unique quality management system adaptable to globalization.
 
With a strong focus on independent innovation and above industry average investment in research and development, MicroPort® holds over 3,500 patents or patent applications. MicroPort® has been awarded the China National Science and Technology Progress Award five times, with one of the awards for company innovation platform model, as well as multiple province and ministry-level science and technology progress awards. As of December 2018, a total of 15 products of MicroPort® have been granted entry into the national green path for the special review and approval of innovative medical devices. The company's diverse Innovation Reaction Furnace, scientific project management mechanism, perfect allocation of hardware resources, comprehensive talent incentive mechanism, and systematic industry cooperation alliance thoroughly ensure the effective operations of the technological innovation system. In September 2018, the results of the large-sale European trial of the Firehawk®, which had been independently developed by MicroPort®, were published on the website of the world leading medical journal the Lancet. This is the first time that clinical data from a China manufactured drug eluting stent has been published in the Lancet since its first publication 200 years ago, showing that the innovative achievement of MicroPort® has won international recognition.
 
MicroPort® adheres to the orientation of the needs of patients and doctors. Centered around quality and driven by innovation, MicroPort® has seen a significantly faster commercialization of its R&D work. MicroPort® actively builds a core brand strategy and sets up a brand management system, bringing about a change in management led by excellent performance. The products of MicroPort® have covered the global mainstream markets, with the core products enjoying a continuously leading domestic market share. The products have also ended the monopoly by international competitors so that they can reduce the financial burden of the patients and lead the rapid development of the industry. The 2018 Shanghai Municipality Gold Quality Prize has fully recognized the strenuous efforts made by MicroPort® with respect to quality management and innovation in research and development. In the future, MicroPort® will continue to follow the management credo of "Eyes for Greatness, Hands on Details", and integrate the pursuit of details and the perseverance in innovation into its corporate gene, while it emphasizes people. On the backdrop of Shanghai's building of a global excellent city, MicroPort® will also innovate relentlessly to commercialize the best and affordable therapeutic solutions to save and reshape or improve patients' lives, and develop the high-tech medical technologies in the world to bring health and longevity to every corner, community, family and patient of the world in a fairer way.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2019 MicroPort Scientific Corporation

CONTACT:
Leanne Li
Board Secretary and Vice President of Corporate General Affairs MicroPort Scientific Corporation
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6953
Email: ir@microport.com